Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels

被引：11
|
作者：
Lujan, Juliana Velez [1 ]
Lengerke-Diaz, Paula A. [2 ]
Jacobs, Chaja [1 ]
Moreno-Cortes, Eider F. [2 ]
Ramirez-Segura, Cesar A. [2 ]
Choi, Michael Y. [1 ]
McCarthy, Colin [1 ]
Heinen, Alaina [1 ]
Kipps, Thomas J. [1 ]
Castro, Januario E. [1 ,2 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
[2] Mayo Clin, Scottsdale, AZ USA
来源：
HAEMATOLOGICA | 2020年 / 105卷 / 01期
关键词：
MONOCLONAL-ANTIBODY; CLL PATIENTS; CHLORAMBUCIL; RELEASE;
D O I：
10.3324/haematol.2018.212597
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E22 / E25
页数：4
相关论文
共 50 条
  • [41] Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE
    Moreno, Carol
    Greil, Richard
    Demirkan, Fatih
    Tedeschi, Alessandra
    Anz, Bertrand
    Larratt, Loree
    Simkovic, Martin
    Samoilova, Olga
    Novak, Jan
    Ben-Yehuda, Dina
    Strugov, Vladimir
    Gill, Devinder
    Gribben, John G.
    Hsu, Emily
    Zhou, Cathy
    Clow, Fong
    James, Danelle F.
    Styles, Lori
    Flinn, Ian W.
    BLOOD, 2018, 132
  • [42] A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Tedeschi, Alessandra
    Greil, Richard
    Demirkan, Fatih
    Robak, Tadeusz
    Moreno, Carol
    Barr, Paul M.
    Anz, Bertrand
    Simpson, David
    Gaidano, Gianluca
    Bairey, Osnat
    Stevens, Don
    Gill, Devinder
    Flinn, Ian W.
    Kipps, Thomas J.
    Burger, Jan A.
    Lin, Jennifer
    Webb, Thomas
    Fedorov, Viktor
    Styles, Lori
    Gribben, John G.
    HAEMATOLOGICA, 2020, 105 (04)
  • [43] CLL Cells from Ibrutinib-Induced Lymphocytosis of Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Are Responsive to Obinutuzumab, but Not Rituximab, Ex Vivo
    Ysebaert, Loic
    Klein, Christian
    Quillet-Mary, Anne
    BLOOD, 2015, 126 (23)
  • [44] Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes
    Rhodes, Joanna M.
    Lore, Vincent A., III
    Mato, Anthony R.
    Chong, Elise A.
    Barrientos, Jacqueline C.
    Gerson, James N.
    Barta, Stefan K.
    Landsburg, Daniel J.
    Nasta, Sunita Dwivedy
    Svoboda, Jakub
    Loren, Alison W.
    Schuster, Stephen J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (07): : 438 - +
  • [45] Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia
    Fresa, Alberto
    Autore, Francesco
    Innocenti, Idanna
    Piciocchi, Alfonso
    Tomasso, Annamaria
    Morelli, Francesca
    Sora, Federica
    Sica, Simona
    De Stefano, Valerio
    Laurenti, Luca
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (03) : 423 - 427
  • [46] Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naive Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Emeribe, Ugochinyere
    Gaitonde, Priyanka
    Cai, Ling
    BLOOD, 2021, 138
  • [47] Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset
    Freeman, Ciara Louise
    Dixon, Mark
    Houghton, Richard
    Humphrey, Kathryn
    Fingerle-Rowson, Gunter
    Kreuzer, Karl-Anton
    Engelke, Anja
    Hallek, Michael
    Goede, Valentin
    BLOOD, 2014, 124 (21)
  • [48] Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia
    Burke, Michael J.
    Rheingold, Susan R.
    LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 540 - 551
  • [49] Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
    Lipsky, Andrew H.
    Farooqui, Mohammed Z. H.
    Tian, Xin
    Martyr, Sabrina
    Cullinane, Ann M.
    Nghiem, Khanh
    Sun, Clare
    Valdez, Janet
    Niemann, Carsten U.
    Herman, Sarah E. M.
    Saba, Nakhle
    Soto, Susan
    Marti, Gerald
    Uzel, Gulbu
    Holland, Steve M.
    Lozier, Jay N.
    Wiestner, Adrian
    HAEMATOLOGICA, 2015, 100 (12) : 1571 - 1578
  • [50] Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
    Freeman, C. L.
    Dixon, M.
    Houghton, R.
    Kreuzer, K-A
    Fingerle-Rowson, G.
    Herling, M.
    Humphrey, K.
    Boettcher, S.
    de Costa, C. S.
    Iglesias, V.
    Stilgenbauer, S.
    Gribben, J.
    Hallek, M.
    Goede, V.
    LEUKEMIA, 2016, 30 (08) : 1763 - 1766
12345